Data / Form D filings / Visgenx, Inc.
Visgenx, Inc.: Form D filings
Visgenx, Inc., a biotechnology company in San Diego, CA, filed 4 Form D notices with the SEC between 2019 and 2023. The latest, on June 14, 2023, reports $2.8 million sold of a $3.5 million offering to 17 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3210 Merryfield Row, San Diego, CA, 92121
- Phone
- (408) 203-5023
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2018
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1783776
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 14, 2023 | New notice | $3,497,724 | $2,763,915 | $733,809 | 17 | Jun 2, 2023 | sec.gov |
| Aug 17, 2020 | Amendment | $5,747,283 | $5,747,283 | 30 | May 11, 2020 | sec.gov | |
| May 20, 2020 | New notice | $5,625,266 | $4,925,263 | $700,003 | 27 | May 11, 2020 | sec.gov |
| Jul 30, 2019 | New notice | $2,200,000 | $655,000 | $1,545,000 | 4 | Jul 12, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Martin Emanuele, Ph.D. | Executive Officer, Director | |
| Thomas Meier, Ph.D., M.D. | Director | |
| Elaine Heron, Ph.D. | Director | |
| William Pedranti | Executive Officer, Director | |
| Arthur Becker | Director | |
| Santosh Vetticaden, Ph.D., M.D. | Director | |
| Eric Carter, Ph.D., M.D. | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Jun 12, 2023 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Visgenx, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.